A groundbreaking at-home test has the potential to transform dementia diagnosis by predicting an individual’s likelihood of developing Alzheimer’s disease. Researchers believe that a simple finger-prick blood test and an online brain assessment could enable widespread screening for the most prevalent type of dementia, pinpointing individuals experiencing early memory and cognitive issues. This home testing method could play a crucial role in identifying those at the highest risk, facilitating prioritized monitoring, diagnosis, and access to necessary treatments and support.
Lead researcher Professor Anne Corbett from the University of Exeter Medical School emphasized the significance of this approach, highlighting its ability to screen individuals for their dementia risk without the need for in-person clinic visits or complex assessments. By identifying those at elevated risk early on, the healthcare system can ensure targeted monitoring and swift access to appropriate interventions for those most in need.
In the UK, nearly one million people are living with dementia, with Alzheimer’s disease being the primary cause in 60% to 80% of cases. Ongoing clinical trials are exploring potential treatments that could be game-changers if administered shortly after early diagnosis. Unfortunately, most dementia cases in the UK are diagnosed late, if at all, underscoring the urgency for improved diagnostic methods.
The recent study, featured in the journal Nature Communications, involved 174 participants who self-administered an at-home test and returned it for analysis. This test, which looked for blood biomarkers p-tau217 and GFAP associated with Alzheimer’s disease and cognitive decline, alongside online brain assessments, yielded promising results.
Dr. Sheona Scales, director at Alzheimer’s Research UK, hailed the potential of finger-prick blood tests in revolutionizing dementia diagnosis by offering a cost-effective and scalable means of identifying individuals at higher risk of Alzheimer’s disease for further evaluation. The study findings indicated the test’s ability to detect changes in blood biomarkers linked to Alzheimer’s and cognitive impairments with high sensitivity.
The research team’s discovery that the blood test, when coupled with cognitive assessments, can effectively gauge an individual’s Alzheimer’s risk is a significant advancement in early detection methods. Professor Clive Ballard from the University of Exeter Medical School stressed the importance of reaching more individuals at risk through a combination of cognitive testing and blood biomarker analysis, providing a practical and cost-efficient approach to identifying those requiring further evaluation and support.
Dr. Scales highlighted the role of self-administered tests in offering reassurance to some individuals and expediting follow-up assessments for others. The accessibility and remote nature of these tests could enhance diagnostic access for those facing logistical challenges in attending specialized clinics.
Going forward, larger and more diverse studies are needed to validate the effectiveness of these diagnostic tools in routine healthcare settings. Professor Ballard encouraged individuals aged over 40 to participate in the online Protect study, which involves regular cognitive assessments for memory, attention, and executive function among more than 30,000 UK adults.
Overall, the development of at-home tests for dementia risk assessment represents a promising step towards early intervention and improved support for individuals at risk of developing Alzheimer’s disease.